These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Almirall, AlmirallShare, atopic dermatitis, dermatological conditions, dermatological research, Dermatology, Dublin City University, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, IDIBAPS, inflammatory diseases, Maribel Crespo, medical dermatology, molecular mechanisms, open innovation platform, Prof. Dr. Lluís Puig, Prof. Silvia Vidal, Prof. Tarl Prow, skin cancer, skin carcinoma, skin health, skin immune cell composition, skin transcriptome, skin tumor, Squamous cell Carcinoma, systemic biomarkers, systemic therapy, topical drugs, University College Dublin, University of Namur, University of Sheffield, University of South Australia, University of Turin
The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau (PRESS RELEASE) HANAU, Germany, 4-Oct-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged affordable skin cancer therapy, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, Dermatology, Dr. Holle, epidermal radioisotope therapies, epidermal radioisotope therapy, first Rhenium-SCT treatment Germany, Garching n. Munich, Hanau Rhenium-SCT treatment center, Healthcare, medical device, medicine, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, Pharma & Biotech, physician, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Rehnium-188, Rhenium, Rhenium-188, Rhenium-SCT, science, Shannon D. Brown III, single-session, skin cancer, Squamous cell Carcinoma, Squamous Cell Carcinomas, technology
New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients. (PRESS RELEASE) Pasadena, CA, U.S.A., 5-Jul-2019 — /EuropaWire/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin … Read the full press release
Posted in Awards, Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged affordable skin cancer therapy, Award, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, Dermatology, epidermal radioisotope therapies, epidermal radioisotope therapy, Garching n. Munich, Healthcare, medical device, medicine, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, Pharma & Biotech, physician, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Red Herring Top 100 North America Award, Rehnium-188, Rhenium, Rhenium-188, Rhenium-SCT, science, Shannon D. Brown III, single-session, skin cancer, Squamous cell Carcinoma, Squamous Cell Carcinomas, technology
The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer (PRESS RELEASE) GARCHING N. MUNICH, Germany, 13-May-2019 — /EuropaWire/ — OncoBeta® GmbH, a commercial stage … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged 1st in Germany, affordable skin cancer therapy, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, Dermatology, Dr. med. Lutz-Hendrik Holle, epidermal radioisotope therapies, epidermal radioisotope therapy, Garching n. Munich, Germany, Hanau, Healthcare, medical device, medicine, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, Pharma & Biotech, physician, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Rehnium-188, Rhenium, Rhenium-188, Rhenium-SCT, Rhenium-SCT treatment center, science, Shannon D. Brown III, single-session, skin cancer, Squamous cell Carcinoma, Squamous Cell Carcinomas, technology
University of Pretoria Prof. Mike Sathekge is First in South Africa to Treat Non-Melanocytic Skin Cancer Patients with Rhenium-SCT® Garching n. Munich, Germany, 26-Nov-2018 — /EuropaWire/ — OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged affordable skin cancer therapy, basal cell carcinoma, Basal Cell Carcinomas, Cancer, carcinomas, epidermal radioisotope therapies, epidermal radioisotope therapy, Garching n. Munich, Martin Magwaza, NMSC, non-invasive, Non-Melanocytic Skin Cancer, non-melanoma skin cancers, nuclear medicine, OncoBeta® GmbH, painless, painless non-invasive skin cancer treatment, painless skin cancer treatment, physician, Prof Mike Sathekge, radioisotope, radioisotope Rhenium-188, radionuclide therapy technology, Rehnium, Rehnium-SCT, Rhenium-188, Rhenium-SCT, Shannon D. Brown III, single-session, skin cancer, South Africa, Squamous cell Carcinoma, Squamous Cell Carcinomas, Steve Biko Academic Hospital, Steve Biko Academic Hospital Nuclear Medical, Tautomer (PTY) LTD, University of Pretoria
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer 19-7-2013 — /europawire.eu/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
